PT  - JOURNAL ARTICLE
AU  - Jordi Juanola Pla
AU  - Ramon Boixeda Viu
AU  - Isabel Moreno Hernandez
AU  - M. Carmen De La Torre Terron
AU  - Maria Bartolomé Regué
AU  - Anna Serrano Fores
AU  - Ainhoa Montero Rodriguez
AU  - Elisabet Palomera Fanegas
AU  - Mateu Serra Prat
AU  - Jordi Almirall Pujol
TI  - Immunoglobulin G and subclasses in COPD exacerbator phenotype: levels in exacerbation time and clinical stability
AID  - 10.1183/13993003.congress-2021.PA3115
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA3115
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA3115.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA3115.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Purpose: To determinate the Immunoglobulin G level and its subclasses in COPD exacerbator phenotype in exacerbation time and to evaluate those levels in clinical stability in same patientsMethods: Prospective observational population-based study. COPD patients who consulted for an exacerbation in 3 health centers or referral hospital were included. During the visit they were classified into 2 groups (exacerbators (E) or non-exacerbators (NE)), defined as exacerbators if they had ≥2 exacerbations in the last year.A clinical questionnaire, blood test with determination of IgG and subclasses and thorax radiography was performed.In clínical stability, after 6 months of exacerbation amb minimal one free month of cortisone and antibiotics, new blood test with determination of IgG and subclasses, in both groups (E/NE), was performed.Results: From November 2016 to March 2019, 295 patients (E: 150, NE: 145) were included: male gender 79.5%, average age 72.2 years (43-94 years). The post-bronchodilator FEV1 55.7% (10-96), considered moderate COPD. Leukocytes 11,965 mm/103uL (2,800-27,760).IgG level in E was in exacerbation 772g/dl vs 877g/dl in stability (p 0.001). IgG level in NE was in exacerbation 862.8g/dl vs 949.4g/dl in stability (p<0.001).The other relevant results of Ig tests are in next tables:Conclusions: Patients with an exacerbator phenotype have lower levels of IgG. Both groups have lower levels in exacerbation time and its recovered in clinical stability.Clinical Implications These results could open a new path by considering the administration of Ig as a possible treatment in these patients to prevent exacerbations.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3115.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).